What is daclatasvir (Daklinza)?
Daclatasvir (Daklinza) is an oral tablet used for the treatment of chronic infection
with the hepatitis C virus (HCV), genotype 1 or 3. It belongs to a class of
drugs called direct-acting antiviral agents (DAAs). Similar drugs include:
- boceprevir (Victrelis)
- sofosbuvir (Sovaldi)
- simeprevir (Olysio)
- telaprevir (Incivek)
- Viekira Pak (ombitasvir, paritaprevir, ritonavir, dasabuvir)
- ledipasvir and sofosbuvir (Harvoni)
- elbasvir and grazoprevir (Zepatier)
What brand names are available for daclatasvir?
Daklinza is the only brand available for daclatasvir in the US.
Is daclatasvir (Daklinza) available as a generic drug?
Do I need a prescription for daclatasvir (Daklinza)?
What are the uses for daclatasvir (Daklinza)?
- Daclatasvir is used in combination with
(Sovaldi) for the treatment of
hepatitis C genotype 1 or 3 infection. It may be used with or without
ribavirin (Rebetol, Ribasphere).
What are the side effects of daclatasvir (Daklinza)?
Common side effects include:
Other side effects include:
Serious side effects include:
- Severe reduction in heart rate (bradycardia) has occurred in people who were treated with daclatasvir and sofosbuvir while also being treated with
- Daclatasvir may cause reactivation of hepatitis B virus (HBV) in people who are infected with HBV and HCV.
Hepatitis C virus causes an infection of the ______________.
What is the dosage for daclatasvir (Daklinza)?
- The recommended dose of daclatasvir is 60 mg once daily with or without food
for 12 weeks.
- Daclatasvir is used in combination with sofosbuvir.
- The dose should be reduced to 30 mg once daily when drugs that block the
breakdown of daclatasvir are being used.
- The dose should be increased to 90 mg once daily when drugs that increase the
breakdown of daclatasvir are being used. (See the drug interactions section for
examples of interacting drugs.)
Which drugs or supplements interact with daclatasvir (Daklinza)?
Daclatasvir has many drug interactions.
St. John’s wort may reduce blood
levels of daclatasvir and reduce its effectiveness by increasing its metabolism
(break-down) in the intestine. Therefore, daclatasvir should not be combined
with rifampin, carbamazepine (Tegretol, Tegretol XR,
Dilantin-125), or St. John's wort.
Other drugs that also may reduce blood levels of Daclatasvir include:
- nafcillin (Nafcil)
- bosentan (Tracleer)
- nevirapine (Viramune)
- efavirenz (Sustiva)
- darunavir (Prezista)
- lopinavir/ritonavir (Kaletra)
- etravirine (Intelence)
- modafanil (Provigil)
Drugs that increase blood levels of daclatasvir by reducing its break
down in the liver include:
(Reyataz) with ritonavir (Norvir)
- clarithromycin (Biaxin)
- nefazodone (Serzone)
- posaconazole (Noxafil)
- telithromycin (Ketek)
Daclatasvir increases blood levels of
Side effects of statins such as muscle pain should
Daclatasvir also increases blood levels of
Latest Digestion News
- COVID Antiviral Pill Approval
- Are Diet Drinks Any Better?
- Diabetes Ups Alzheimer’s Risk
- Key Protein in TBI Patients
- Breastfeeding Helps Postpartum Depression
- More Health News »
Trending on MedicineNet
- Breast Cancer Warning Signs
- CMT Disease
- Main Cause of Graves’ Disease
- RSV in Adults
- Ehlers-Danlos Syndrome
Is daclatasvir (Daklinza) safe to use during pregnancy or while breastfeeding?
- Daclatasvir has not been adequately evaluated in
pregnant women. However,
ribavirin, which may be combined with daclatasvir, should not be used by
pregnant women or their male partners.
- It is not known whether daclatasvir is secreted into breast milk.
What else should I know about daclatasvir (Daklinza)?
What preparations of daclatasvir (Daklinza) are available?
- Tablets: 30 and 60 mg
How should I keep daclatasvir (Daklinza) stored?
- Daclatasvir should be stored at room temperature, between 20 C to 25
C (68 F to 77 F).
How does daclatasvir (Daklinza) work?
- Daclatasvir directly blocks replication of HCV by interfering with a
hepatitis C virus protein called nonstructural protein 5A (NS5A). Daclatasvir
interferes with proteins and processes needed by hepatitis C virus to multiply
and make new viruses, thus reducing the overall viral load. The efficacy of
Daclatasvir has been established in subjects with hepatitis C virus genotypes 1
- Daclatasvir is given with sofosbuvir and may be administered with or without
ribavirin. In clinical studies, 95% of patients were cured after 12 weeks of
treatment with daclatasvir plus sofosbuvir with or without ribavirin. Cure was
defined as undetectable levels of hepatitis C virus in the blood when measured
three months after the completion of treatment.
When was daclatasvir (Daklinza) approved by the FDA?
- The FDA approved daclatasvir in